Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
Perusini MA, Andrews C, Atenafu EG, Gupta V, Maze D, Schuh AC, Yee KW, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Sibai J, Schimmer AD, Minden MD, Sibai H. Perusini MA, et al. Among authors: richard carpentier g. Hematology. 2024 Dec;29(1):2329027. doi: 10.1080/16078454.2024.2329027. Epub 2024 Mar 25. Hematology. 2024. PMID: 38526239
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
Perusini MA, Andrews C, Eshetu AG, Gupta V, Maze D, Yee KWL, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Schimmer AD, Sibai J, Alharbi S, Lucero JA, Linn SM, Minden MD, Schuh AC, Sibai H. Perusini MA, et al. Among authors: richard carpentier g. Leukemia. 2024 Apr;38(4):912-913. doi: 10.1038/s41375-024-02201-1. Epub 2024 Mar 2. Leukemia. 2024. PMID: 38431747 No abstract available.
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB, Kennedy JA, Capo-Chichi JM, Shi Y, Xu W, Cheung V, Arruda A, Bankar A, Richard-Carpentier G, Chan S, Maze D, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee K, Tierens A, Viswabandya A, Gupta V. Davidson MB, et al. Among authors: richard carpentier g. Blood Adv. 2024 Mar 12;8(5):1281-1294. doi: 10.1182/bloodadvances.2023011735. Blood Adv. 2024. PMID: 38170760 Free PMC article.
Impact of secondary-type mutations in NPM1 mutated AML.
Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H. Zhou Q, et al. Among authors: richard carpentier g. Eur J Haematol. 2023 Jul;111(1):165-168. doi: 10.1111/ejh.13979. Epub 2023 May 10. Eur J Haematol. 2023. PMID: 37165755 No abstract available.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Richard-Carpentier G, et al. Haematologica. 2023 Sep 1;108(9):2331-2342. doi: 10.3324/haematol.2022.282030. Haematologica. 2023. PMID: 36951163 Free PMC article.
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: richard carpentier g. Nat Med. 2022 May;28(5):1097. doi: 10.1038/s41591-022-01827-x. Nat Med. 2022. PMID: 35484266 Free PMC article. No abstract available.
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: richard carpentier g. Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3. Nat Med. 2022. PMID: 35241842 Free PMC article.
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience.
Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Richard-Carpentier G, et al. Blood Adv. 2021 Dec 14;5(23):5415-5419. doi: 10.1182/bloodadvances.2021004580. Blood Adv. 2021. PMID: 34525185 Free PMC article.
Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
Ferrone CK, Wong H, Semenuk L, Werunga B, Snetsinger B, Zhang X, Zhang G, Lui J, Richard-Carpentier G, Crocker S, Good D, Hay AE, Quest G, Carson N, Feilotter HE, Rauh MJ. Ferrone CK, et al. Among authors: richard carpentier g. J Mol Diagn. 2021 Oct;23(10):1292-1305. doi: 10.1016/j.jmoldx.2021.07.010. Epub 2021 Aug 5. J Mol Diagn. 2021. PMID: 34365012 Free article.
23 results